Eliem Therapeutics Analyst Ratings
Eliem Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 08/16/2022 | 19.76% | SVB Leerink | $9 → $4 | Maintains | Outperform |
| 07/11/2022 | 169.46% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 289.22% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 858.08% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 947.9% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 888.02% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 02/10/2023 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 10/28/2022 | 79.64% | HC Wainwright & Co. | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/16/2022 | 19.76% | SVB Leerink | 9 美元 → 4 美元 | 維持 | 跑贏大盤 |
| 2022 年 11 月 7 日 | 169.46% | SVB Leerink | 13 美元 → 9 美元 | 維持 | 跑贏大盤 |
| 04/26/2022 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 04/26/2022 | 289.22% | SVB Leerink | 33 美元 → 13 美元 | 維持 | 跑贏大盤 |
| 09/07/2021 | 858.08% | 古根海姆 | → 32 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/07/2021 | 947.9% | Stifel | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/07/2021 | 888.02% | SVB Leerink | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Eliem Therapeutics (ELYM)?
Eliem Therapeutics（ELYM）的目標價格是多少？
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on February 10, 2023. The analyst firm set a price target for $0.00 expecting ELYM to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年2月10日公佈了Eliem Therapeutics（納斯達克股票代碼：ELYM）的最新目標股價。該分析公司將目標股價設定爲0.00美元，預計ELYM將在12個月內跌至0.00美元（可能下跌-100.00％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Eliem Therapeutics (ELYM)?
Eliem Therapeutics（ELYM）的最新分析師評級是多少？
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics downgraded their neutral rating.
Eliem Therapeutics（納斯達克股票代碼：ELYM）的最新分析師評級由HC Wainwright & Co. 提供，Eliem Therapeutics下調了中性評級。
When is the next analyst rating going to be posted or updated for Eliem Therapeutics (ELYM)?
Eliem Therapeutics（ELYM）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on February 10, 2023 so you should expect the next rating to be made available sometime around February 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Eliem Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Eliem Therapeutics的最後一次評級是在2023年2月10日發佈的，因此您應該預計下一個評級將在2024年2月10日左右公佈。
Is the Analyst Rating Eliem Therapeutics (ELYM) correct?
分析師評級Eliem Therapeutics（ELYM）是否正確？
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.34, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Eliem Therapeutics（ELYM）評級下調，目標股價爲0.00美元至0.00美元。Eliem Therapeutics（ELYM）目前的交易價格爲3.34美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。
